Investigating the specific uptake of EGF-conjugated nanoparticles in lung cancer cells using fluorescence imaging
暂无分享,去创建一个
Honglin Jin | Jonathan F. Lovell | Gang Zheng | Weiguo Cao | Zhihong Zhang | J. Lovell | G. Zheng | Juan Chen | Kenneth K. Ng | Honglin Jin | Zhihong Zhang | Juan Chen | Lili Ding | W. Cao | Kenneth Ng | L. Ding
[1] J. Doroshow. Targeting EGFR in non-small-cell lung cancer. , 2005, The New England journal of medicine.
[2] R. Senekowitsch-Schmidtke,et al. In vivo evaluation of epidermal growth factor (EGF) receptor density on human tumor xenografts using radiolabeled EGF and anti-(EGF receptor) mAb 425 , 1996, Cancer Immunology, Immunotherapy.
[3] Hui Li,et al. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[4] S. Ståhl,et al. Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry , 2009, Journal of Nuclear Medicine.
[5] Warren C W Chan,et al. Nanoparticle-mediated cellular response is size-dependent. , 2008, Nature nanotechnology.
[6] J. Xie,et al. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. , 2010, Biomaterials.
[7] Qingming Luo,et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. , 2010, Small.
[8] P. Couvreur,et al. Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.
[9] T. Aizawa,et al. Peptide mimics of epidermal growth factor (EGF) with antagonistic activity. , 2005, Journal of biotechnology.
[10] T. Schneider-Merck,et al. Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor1 , 2007, The Journal of Immunology.
[11] Helen H. Hobbs,et al. Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.
[12] Joseph M. DeSimone,et al. Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.
[13] S. Seal,et al. Protonated nanoparticle surface governing ligand tethering and cellular targeting. , 2009, ACS nano.
[14] T Lammers,et al. Tumour-targeted nanomedicines: principles and practice , 2008, British Journal of Cancer.
[15] Xinying Wu,et al. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. , 2010, Biomaterials.
[16] J. Gariépy,et al. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] Qingming Luo,et al. Biomimetic nanocarrier for direct cytosolic drug delivery. , 2009, Angewandte Chemie.
[18] Gang Zheng,et al. Enhanced Cancer-Targeted Delivery Using Engineered High-density Lipoprotein-Based Nanocarriers , 2007 .
[19] Lisa Brannon-Peppas,et al. Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.
[20] G Poste,et al. Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[21] U. Gatzemeier. Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer. , 2003, Oncology.
[22] L. Brannon-Peppas,et al. Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.